5 Stocks With Recent Price Strength Buoyed by a Strong August
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Zacks Investment Research9/4/2026Positive
DCTH
Delcath Systems IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$571.84M
P/E Ratio
1648.00
EPS
$0.01
Beta
0.57
52W High
$17.42
52W Low
$8.12
50-Day MA
$14.45
200-Day MA
$11.26
Dividend Yield
—
Profit Margin
0.56%
Forward P/E
238.10
PEG Ratio
1.60
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $95.42M |
| Gross Profit (TTM) | $83.06M |
| EBITDA | $-1.46M |
| Operating Margin | 8.22% |
| Return on Equity | 0.47% |
| Return on Assets | -0.89% |
| Revenue/Share (TTM) | $2.64 |
| Book Value | $3.50 |
| Price-to-Book | 4.72 |
| Price-to-Sales (TTM) | 5.99 |
| EV/Revenue | 5.01 |
| EV/EBITDA | 294.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.60% |
| Shares Outstanding | $34.70M |
| Float | $28.78M |
| % Insiders | 8.09% |
| % Institutions | 51.72% |
Historical Volatility
HV 10-Day
21.72%
HV 20-Day
45.56%
HV 30-Day
74.55%
HV 60-Day
59.95%
HV Rank
92.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($24.00 target)
1
Strong Buy4
BuyLatest News
What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research8/28/2026Positive
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research8/28/2026Positive
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research8/27/2026Positive
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research8/12/2026Positive
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research8/11/2026Positive
Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research8/11/2026Positive
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
Delcath Systems Q2 Earnings Call Highlights
Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.
MarketBeat8/6/2026Positive
Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.
Zacks Investment Research8/6/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DCTH and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026